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Abstract
Dysregulated signaling cascades alter energy metabolism and promote cell proliferation
and cyst expansion in polycystic kidney disease (PKD). Here we tested whether metabolic
reprogramming towards aerobic glycolysis (“Warburg effect”) plays a pathogenic role in
male heterozygous Han:SPRD rats (Cy/+), a chronic progressive model of PKD. Using
microarray analysis and qPCR, we found an upregulation of genes involved in glycolysis
(Hk1, Hk2, Ldha) and a downregulation of genes involved in gluconeogenesis (G6pc, Lbp1)
in cystic kidneys of Cy/+ rats compared with wild-type (+/+) rats. We then tested the effect of
inhibiting glycolysis with 2-deoxyglucose (2DG) on renal functional loss and cyst progres-
sion in 5-week-old male Cy/+ rats. Treatment with 2DG (500 mg/kg/day) for 5 weeks
resulted in significantly lower kidney weights (-27%) and 2-kidney/total-body-weight ratios
(-20%) and decreased renal cyst index (-48%) compared with vehicle treatment. Cy/+ rats
treated with 2DG also showed higher clearances of creatinine (1.98±0.67 vs 1.41±0.37 ml/
min), BUN (0.69±0.26 vs 0.40±0.10 ml/min) and uric acid (0.38±0.20 vs 0.21±0.10 ml/min),
and reduced albuminuria. Immunoblotting analysis of kidney tissues harvested from 2DG-
treated Cy/+ rats showed increased phosphorylation of AMPK-α, a negative regulator of
mTOR, and restoration of ERK signaling. Assessment of Ki-67 staining indicated that 2DG
limits cyst progression through inhibition of epithelial cell proliferation. Taken together, our
results show that targeting the glycolytic pathway may represent a promising therapeutic
strategy to control cyst growth in PKD.
Introduction
Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic renal
disease, characterized by progressive development of innumerable cysts in both kidneys. The
development and relentless growth of cysts lead to kidney enlargement and compression of
renal parenchyma, leading to subsequent loss of renal function [1,2]. Recent studies have indi-
cated that various signaling cascades are dysregulated in ADPKD, including activation of
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mTOR and downregulation of AMPK signaling, and enhanced vasopressin-mediated cAMP
and ERK signaling [3,4,5,6]. Favourable results from several clinical trials targeting these path-
ways have led to the development of therapeutic concepts for ADPKD, yet treatment is not
available for the majority of patients [7].
A promising strategy to achieve therapeutic selectivity and efficacy in ADPKD is to take
advantage of the fundamental difference between cyst epithelial cells and normal epithelial
cells in their energy metabolism. A recent study by Rowe et al. has shown that glycolysis was
enhanced in a mouse model of ADPKD and also in kidney tissues from patients with ADPKD
[8]. Metabolomic profiling of extracellular medium of embryonic fibroblast cultures derived
from Pkd1-/- and Pkd1+/+ mice indicated increased glucose uptake and lactate production and
enhanced glycolytic enzyme gene expression in the mutant cells [8]. Using 2-deoxyglucose
(2DG), an analog of glucose that blocks glycolysis, they found that cyst growth could be inhib-
ited in rapidly progressing mouse models of polycystic kidney disease (PKD). Although the
tested models did not allow for assessment of renal function, the data suggested that targeting
glycolysis might represent a novel therapeutic strategy in ADPKD.
The purpose of the present study was to extend the above observations and to examine
whether 2DG could be used in a chronic progressive rat model of PKD. Here we show that cys-
tic kidneys in Han:SPRD rats display metabolic reprogramming in the sense of a ‘Warburg
effect’ and that 2DG improved renal functional loss and cyst progression through normaliza-
tion of intracellular signaling pathways.
Methods
Animals
The Han:SPRD rat colony was established in our animal facility from a litter which was
obtained from the Rat Resource and Research Center (Columbia, MO, USA). Heterozygous
cystic (Cy/+) and wild type normal (+/+) rats were used in this study. Han:SPRD rats carry a
missense mutation in Anks6 (also called Pkdr1), leading to an R823W substitution in SamCys-
tin, a protein that contains ankyrin repeats and a sterile alpha motif (SAM) [9]. Han:SPRD Cy/
+ rats develop a slowly progressing form of PKD which resembles phenotypically human
ADPKD [10]. Only male rats were used in this study since cysts develop more rapidly in male
compared with female rats [11]. The protocol has been approved by the committee on the Eth-
ics of Animals Experiments at the University of Zurich (Licence Number: 174–2013). Rats had
free access to tap water and standard rat diet.
Genechip expression analysis
Affymetrix GeneChip1 rat genome 230 2.0 arrays were used according to the manufacturer's
instructions (Affymetrix Inc., Santa Clara, CA, USA). Briefly, 5 μg of total RNA from 5-week old
Cy/+ and +/+ rat kidneys was used as starting material to generate biotin-labeled cRNA samples,
which includes cDNA synthesis using oligo-dT/T7 primers, followed by in vitro transcription
(one-cycle labeling protocol). Labeled cRNA samples (15 μg) were randomly fragmented to 35–
200 bp and hybridized on arrays for 16 h. After washing the arrays the fluorescent intensity emit-
ted by the labeled targets was measured by an Affymetrix GeneChip1 Scanner 3000. Finally, the
hybridization images were analyzed using Affymetrix GCOS 1.2 software.
Reverse transcription and real-time PCR
RT-PCR analyses were performed as described previously [12,13]. Total RNA was reverse-
transcribed and PCR was carried out using SYBR1 Green JumpStart Taq ReadyMix (Sigma-
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Aldrich, St Louis, MO, USA). Real-time PCR analyses were performed with the ABI PRISM
7500 Sequence Detection System (Applied Biosystems, Rotkreuz, Switzerland), according to
the instructions of Applied Biosystems. The expression levels of β-actin were used as a house-
keeping gene. Relative quantification of all targets was calculated by the comparative cycle
threshold method outlined by the manufacturer (User Bulletin No. 2; Applied Biosystems,
Rotkreuz, Switzerland).
Experimental protocol
Male Cy/+ and +/+ rats were weaned and then treated at 5 weeks of age with 500 mg/kg/day
2DG (Cy/+: n = 10; +/+: n = 10) or vehicle NaCl (Cy/+: n = 10; +/+: n = 10) by daily subcutane-
ous injection for 5 weeks throughout the treatment phase. The dose of 2DG or vehicle was
adjusted daily to the body weight of the rats. For blood collection, rats were anesthetized with
inhalation of 1.5–3.5% isoflurane. Metabolic cages were used to collect 24-hour urine samples
and to monitor food and fluid intake. Rats were acclimatized to the metabolic cage for an hour
every day for three consecutive days prior to the actual metabolic cage experiment. All animals
were sacrificed at week 10 by CO2 euthanasia.
Blood and urine chemistries
Plasma and 24-hour urines were collected from rats at week 5, 7.5 and 10 and aliquots were
rapidly frozen and stored at -80°C until measurement. Glucose, sodium, chloride, creatinine,
blood urea nitrogen (BUN) and uric acid concentrations were determined in plasma and urine
using a Cobas 8000 Modular Analyzer from Roche Diagnostics AG (Rotkreuz, Switzerland).
Plasma and urine osmolality were measured by using an Advanced Osmometer Model 2020
(Advanced Instruments Inc., Norwood, MA, USA). Urinary albumin concentration was deter-
mined using a rat albumin ELISA kit (Genway, San Diego, CA, USA), as previously described
[14]. Albuminuria was expressed as total urinary albumin excretion over 24-hour. Urine pro-
teins were also analyzed by non-reducing SDS-PAGE and Coomassie blue staining.
Tissue processing, periodic acid-Schiff staining, and cyst index
measurement
At the age of 10 weeks, all rats were sacrificed and kidneys were excised, decapsulated and
weighed. For histological examination, one of the kidneys from each animal was sliced perpen-
dicularly to the long axis at approximately 2 mm intervals. Slices from the midportion of the
kidneys were fixed in 4% buffered formalin and submitted to subsequent paraffin embedding.
Serial sections of 3 μm thickness per paraffin block were cut and stained with periodic acid-
Schiff (PAS) following a routine protocol. The stained sections were subjected to cyst index
analysis, using the HistoQuest image analysis software (TissueGnostics, Vienna, Austria) to
determine the cyst area (CA) and the total area (TA). The cyst index was calculated as CA/
TA100.
Immunohistochemical detection of proliferation
Immunohistochemistry for Ki67 was performed on 3-μm tissue sections. In brief, the tissue
sections were deparaffinized and rehydrated. The antigen retrieval was performed in an auto-
clave oven. Primary mouse anti-Ki67 antibody (BD Pharmingen, San Jose, CA, USA) and bioti-
nylated secondary antibody (Vector, Los Angeles, CA, USA) were used. This was followed by
the application of the ABC reagent, using 3,3’-diaminobenzidine with metal enhancement as
the detection reagent. The stained sections were subjected to analysis using the HistoQuest
Glycolytic Inhibition in PKD
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image analysis software (TissueGnostics, Vienna, Austria) to quantify the number of Ki67-po-
sitive nuclei over the total area of the kidney section.
Primary TEC cultures
Primary cultures of renal tubular epithelial cells (TECs) from 10-week-old +/+ and Cy/+ kid-
neys were prepared by mincing the kidneys and digesting the tissues with 1 mg/ml collagenase
with gentle agitation for 1 h at 37°C. The suspension was allowed to sediment for 1 min. Cells
were collected by harvesting the supernatant twice, and were then washed three times with
10% fetal bovine serum (FBS)/Hanks balanced salt solution. Isolated cells were resuspended in
K1 medium (1:1 mixture of Dulbecco’s modified Eagle’s medium and Ham’s F-12 medium
supplemented with 5% FBS, 10 mmol/l HEPES, 42 mmol/l sodium bicarbonate, 50 ng/ml insu-
lin, 50 nmol/l hydrocortisone, 50 ng/ml transferrin, 5 pmol/l triiodothyronine, 20 ng/ml rat
EGF, 100 IU/ml penicillin, and 100 μg/ml streptomycin). Cells were then seeded in collagen
type 1–precoated culture dishes and grown to confluence. The medium was changed to a K1
medium with 0.5% FBS for 24 h, and the cells were then incubated with 2DG at various con-
centrations for 24 h. Cell viability was assessed by MTS assay following standard protocols.
Normal human kidney epithelial cells (NHK) were obtained from ATCC (ATCC1 PCS-
400-010™, Manassas, VA, USA). ADPKD cells were prepared from nephrectomy material as
previously described [15], after obtaining ethical approval from the ethics committee of the
canton of Zurich, Switzerland, and informed oral consent. The culture conditions for ADPKD
and NHK cells were similar to that of rat primary renal tubular epithelial cells.
Western blotting analysis
Snap frozen kidney tissue was homogenized and tissue lysates or cell culture lysates were
resolved by SDS–polyacrylamide gel electrophoresis, transferred to nitrocellulose membranes,
and probed with primary antibodies. Mouse anti-Phospho-p70-S6K (Thr389), rabbit anti-
p70-S6K mouse anti-Phospho-Erk1/2 (Thr202/Tyr24), rabbit anti-Erk1/2, rabbit anti-Phos-
pho-AMPKα (Thr172), mouse-anti-Phospho-Akt (Ser473), rabbit anti-Akt and anti-caspase-3
antibodies were obtained from Cell signaling Technology, Beverly, MA, USA. Mouse anti-
AMPKα was obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-mouse
and anti-rabbit secondary antibodies were purchased from Licor Biosciences (Lincoln,
Nebraska, USA).
ATP and lactate quantification
Intracellular ATP was quantified by luciferase activity according to the standard protocol in
the ATP Determination kit (Invitrogen, Life Technologies, Zug, Switzerland). The concentra-
tion of lactate in cell culture supernatants and in kidney tissue from Han:SPRD rats was mea-
sured using the EnzyChrom L-lactate Assay Kit (BioAssay Systems, Hayward, USA), according
to the manufacturer’s instructions.
In vitro BrdU Proliferation Assay
In vitro proliferation of primary TEC was analyzed with the colorimetric cell proliferation
BrdU assay kit (Roche Applied Science, Indianapolis, USA) according to the manufacturer’s
instruction. Briefly, cells were cultured in 96-well plates with or without 2DG. After 48 hours,
cells were labeled using 10 μM BrdU per well and re-incubated overnight at 37°C in a humidi-
fied atmosphere. The next day, the culture media was removed, the cells were fixed, and the
DNA was denatured in one step by adding FixDenat solution. Cells were incubated with anti-
Glycolytic Inhibition in PKD
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BrdU-POD antibody, washed and the substrate solution was added. The reaction product was
quantified by measuring the absorbance using a spectrophotometer at 370 nm with a reference
wavelength of 492 nm.
In vitro Cell Apoptosis Assay
Cells were cultured in 6-well plates with or without 2DG at a concentration of 1, 5, and 10 mM.
After 24 hours, cells were collected following detachment with trypsin, resuspended in 140
mMNaCl, 10 mMHEPES, and 2.5 mM CaCl2 and incubated with annexin V-FITC (Roche
Diagnostics, Basel, Switzerland) for 30 minutes at room temperature according to the manufac-
turer’s instructions. Flow cytometric analyses were performed using a BD-FACScan flow
cytometer (BD Biosciences, San Jose, CA, USA). Data were analyzed using FlowJo software
(Treestar Inc., Ashland, OR, USA.).
Statistical analyses
All data are expressed as means ± SEM unless otherwise stated. Statistical analyses were per-
formed using Student’s-t-test and ANOVA with Dunnett post-hoc test for multiple comparison
analysis using GraphPad Prism version 5.0 (Graph Pad Inc., San Diego, CA, USA). A value of
P<0.05 was considered as statistically significant.
Results
Increased glycolysis and decreased gluconeogenesis in polycystic
kidney disease
First we performed microarray gene expression analysis on mRNA transcripts from kidney tis-
sues from Han:SPRD Cy/+ and wild-type +/+ male rats to examine the glycolysis and the glu-
coneogenesis pathways of glucose metabolism. The microarray results are available online
(accession number GSE75578) at the NCBI Gene Expression Omnibus (GEO). The mRNA lev-
els of several genes involved in the glycolysis pathway were upregulated, whereas transcript lev-
els of genes encoding for enzymes in gluconeogenesis were significantly donwregulated (Fig 1A
and 1B). This observation was confirmed by quantitative real-time PCR analysis which demon-
strated upregulation of key genes involved in the glycolysis pathway (Hk1, Hk2, Ldha) and
downregulation of key genes involved in the gluconeogenesis pathway (Fbp1, Fbp2, G6pc) in
the kidney tissues of Cy/+ rats versus +/+ rats (Fig 1C). Furthermore, upregulation ofHk1 and
Hk2 genes was also observed in primary cell cultures of human ADPKD as compared to con-
trol primary cultures of normal human kidney (NHK) epithelial cells (Fig 1D).
To extend these observations we measured the intracellular ATP levels and the production
of lactate in vitro using primary cell cultures of tubular epithelial cells isolated from kidneys of
Cy/+ versus +/+ rats. The intracellular ATP levels were significantly increased in the Cy/+ cell
cultures as compared to +/+ cell cultures, and were decreased upon incubation of Cy/+ cells
with 2DG (Fig 2A). Furthermore, the lactate content in the cell culture media was higher in
Cy/+ cell cultures in comparison to +/+ cell cultures, and was also decreased upon incubation
of Cy/+ cells with 2DG (Fig 2B). No significant changes in the intracellular ATP levels or lac-
tate content in the cell culture media were observed when +/+ cells were incubated with 2DG
(Fig 2A and 2B). Similar observations were obtained in the primary cell cultures of human
ADPKD and NHK cells; intracellular ATP levels and lactate in the cellular medium were higher
in ADPKD cells as compared to NHK cells, and the levels were diminished upon incubation of
ADPKD cells with 2DG (Fig 2D and 2E).
Glycolytic Inhibition in PKD
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Fig 1. Dysregulation of the glycolysis and gluconeogenesis pathways in rat polycystic kidney disease. (A) Microarray analysis showing differential
expression of genes coding for glycolysis and gluconeogenesis enzymes in Han:SPRD Cy/+ and wild-type +/+ kidneys. Upregulated genes are shown in red,
and downregulated genes are shown in green. (B) Schematic diagram showing the glycolysis/gluconeogenesis cascades. In red, upregulated genes; green,
downregulated genes; black, genes unchanged in kidneys from Cy/+ rats compared with wild-type +/+ kidneys. (C) Real-time quantitative PCR analysis of
genes coding for key enzymes involved in glycolysis/gluconeogenesis in kidneys from Cy/+ rats and +/+ rats. (D) Real-time quantitative PCR analysis of the
hexokinase-1 (Hk1) and hexokinase-2 (Hk2) genes in primary cell cultures of human ADPKD and control NHK cells. The expression levels of β-actin were
used as a housekeeping gene.
doi:10.1371/journal.pone.0146654.g001
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Fig 2. Increased glycolytic phenotype in polycystic kidney disease. (A) Intracellular ATP content in primary cell cultures of tubular epithelial cells
isolated from kidneys of Cy/+ and +/+ rats. (B) Lactate concentration in the medium of primary cell cultures of tubular epithelial cells isolated from kidneys of
Cy/+ and +/+ rats. (C) Cell growth of primary renal Cy/+ cells upon incubation with increasing concentrations of 2DG, as assessed by the MTS assay. (D)
Intracellular ATP content in primary cell cultures of ADPKD and NHK cells. (E) Lactate concentration in the medium of primary cell cultures of ADPKD and
NHK cells. (F) Effect of 2DG on cell proliferation of human ADPKD cells and control NHK cells, as quantified by BrdU assay. (G) Effect of 2DG on apoptosis
of human ADPKD cells and control NHK cells, as analyzed with annexin-V/propidium iodide (PI) staining using flow cytometry.
doi:10.1371/journal.pone.0146654.g002
Glycolytic Inhibition in PKD
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To analyze the effect of 2DG on cell proliferation and apoptosis we incubated primary renal
tubular epithelial cells from Cy/+ rats with increasing concentrations of 2DG and found
reduced cellular growth, as measured by the MTS assay (IC50 = 5.1 mM, Fig 2C). We also eval-
uated the effect of 2DG on cell proliferation and apoptosis of primary cultures of human
ADPKD cells and control NHK cells. Incubation with 2DG limited cell proliferation (BrdU
assay) and increased apoptosis (annexin-V staining) of primary human ADPKD cells in con-
centration-dependent manner (Fig 2F and 2G). Of note, the effects of 2DG on cell proliferation
and apoptosis were more pronounced on ADPKD cells than on NHK cells, indicating a thera-
peutic potential of 2DG in human ADPKD (Fig 2F and 2G).
In vivo effect of 2DG treatment
Effect of 2DG treatment on kidney weight and morphology. To assess the in vivo effect
of glycolysis inhibition on cyst development and disease progression, we examined the effects
of 2DG treatment in Han:SPRD Cy/+ and +/+ control rats. Rats were treated with 500 mg/kg/
day 2DG or vehicle NaCl daily for 5 weeks. Based on the human equivalent dose [16], the
amount of 2DG administered is equivalent to approximately 81 mg/kg/day in human. A previ-
ous study has reported 63 mg/kg/day to be the clinically tolerable dose for human clinical trials,
with reversible side effects observed at a dose range of 63–88 mg/kg/day [17]. The dose used in
the current proof-of-concept study should therefore not lead to any significant irreversible
adverse effects.
The 5-week treatment with 2DG was generally well tolerated in both animal groups. Side
effects included lower body weight and mildly increased diuresis in 2DG-treated Cy/+ and
+/+ rats. There were no significant changes in the plasma Na+ and Cl−, and no difference in
plasma glucose levels between 2DG- and vehicle-treated Cy/+ and +/+ rats. At the end of the
5-week treatment phase, the total weight of both kidneys was significantly lower in 2DG-
treated Cy/+ rats in comparison with vehicle-treated Cy/+ rats (-27.2%, P<0.001; Table 1). The
2-kidneys/body weight ratio was also lower upon 2DG treatment in Cy/+ rats as compared to
vehicle treatment (-20.4%, P<0.01; Table 1, Fig 3A and 3B).
Table 1. Effect of 2DG treatment on kidney and body weight.
+/+ Cy/+
Baseline Week 2.5 Week 5 Baseline Week 2.5 Week 5
Vehicle 2DG Vehicle 2DG Vehicle 2DG Vehicle 2DG
Number of
animals (n)
20 10 10 10 10 20 10 10 10 10
Age (in weeks) 5 7.5 7.5 10 10 7.5 7.5 10 10
Body Weight (g) 161.4
(17.5)
284.7
(17.9)
266.8
(25.5)
339.2
(28.2)
328
(24.6)
167.4
(20.0)
290.1
(33.2)
263.1
(25.3)
345.0
(31.5)
317.1*
(26.0)
Total kidney
weight (g)
2.38
(2.66)
2.35
(1.75)
8.67
(1.46)
6.31***
(1.14)
%TKW/BW 0.70
(0.06)
0.72
(0.04)
2.50
(0.29)
1.99**
(0.30)
Data are presented as means and standard deviations (in parentheses).
*P<0.05,
**P<0.01,
***P<0.001 when comparing 2DG- versus vehicle-treated groups at each time point. TKW/BW, total kidney weight divided by body weight.
doi:10.1371/journal.pone.0146654.t001
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Histomorphological examination of the kidney sections showed that vehicle-treated Cy/
+ rats had enlarged kidneys with multiple cysts which were not present in +/+ rats, as expected
(Fig 3A). Treatment with 2DG resulted in a reduced size of the kidneys and reduced cyst sizes
in Cy/+ rats compared with vehicle treatment (Fig 3A). Furthermore, quantification of the
number of cysts on periodic acid Schiff-stained sections showed a significant reduction of the
cyst index in 2DG-treated Cy/+ rats as compared to vehicle treatment (Fig 3C). Frequency dis-
tribution analysis of the cyst size showed that treatment with 2DG led to a shift in the size pro-
file of the cysts (Fig 3D). The total number of cysts was similar in 2DG- and vehicle-treated
rats (Fig 3E), suggesting that 2DG treatment affected cyst growth rather than cyst development
in Cy/+ rats.
Effect of 2DG treatment on renal function. We then evaluated the effects of 2DG treat-
ment on the parameters of renal function. Cy/+ rats developed significant impairment of renal
function as compared to +/+ rats (Fig 4A, 4B and 4C). Following treatment with 2DG, Cy/
Fig 3. Effect of 2DG treatment on kidney weight andmorphology in Han:SPRDCy/+ rats. (A) Representative images of periodic acid-Schiff staining of
kidneys from 10 week old +/+ and Cy/+ rats after 5-week treatment with 2DG or vehicle. (B) Ratio of total kidney weight (TKW) to body weight (BW) in 10
week old Cy/+ rats after 5-week treatment with 2DG or vehicle. (C). Cyst index in kidneys from Cy/+ rats after 5-week treatment with 2DG or vehicle. (D)
Frequency distribution of the cyst size, and (E) total number of cysts, in kidneys from Cy/+ rats following 5-week treatment with 2DG or vehicle.
doi:10.1371/journal.pone.0146654.g003
Glycolytic Inhibition in PKD
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+ rats had lower plasma creatinine levels as compared to vehicle treatment, with significantly
higher clearances for creatinine (Fig 4A), BUN (Fig 4B) and uric acid (Fig 4C). Furthermore,
the albumin excretion following treatment with 2DG was significantly lower as compared to
vehicle-treated Cy/+ rats (Fig 4D and 4E). Lactate content in the kidneys of vehicle-treated Cy/
+ rats were significantly higher than in vehicle-treated +/+ rats (Fig 4F). Treatment with 2DG
reduced the level of lactate in the kidneys of Cy/+ rats when compared to vehicle treatment
(Fig 4F).
Effect of 2DG treatment on cell proliferation and apoptosis. To examine whether 2DG
reduces cyst epithelial cell proliferation we stained kidney sections for Ki67 and found a
marked reduction in Ki67-positive nuclei in the tubular epithelium of Cy/+ kidneys as com-
pared to vehicle treatment (Fig 5A and 5B). We also tested for apoptosis, examining active cas-
pase-3 expression by Western blot analysis of kidney tissues from the Cy/+ rats. We found no
difference in the level of active caspase-3 expression after treatment with 2DG as compared to
vehicle treatment (Fig 5C). These data suggest that 2DG limits cyst growth in Cy/+ rats by
inhibiting cell proliferation rather than by promoting apoptosis in the cystic epithelium.
Effect of 2DG treatment on cellular signaling pathways. To further characterize the
mechanisms of the increased glycolysis observed in Han:SPRD rats, we assessed the effect of
2DG on important signaling pathways that have previously been shown to be dysregulated in
ADPKD. First, we examined the effect of 2DG on the phosphorylation of AMPK-α, an impor-
tant negative regulator of mTOR, which has been shown to be reduced in PKD.
Fig 4. Effect of 2DG treatment on parameters of renal function.Measurement of (A) creatinine clearance, (B) BUN clearance, and (C) uric acid
clearance, in +/+ and Cy/+ rats upon treatment with 2DG or vehicle at baseline, 2.5 weeks and 5 weeks. Black, +/+ treated with vehicle; blue, +/+ treated with
2DG; red, Cy/+ treated with vehicle; green, Cy/+ treated with 2DG. *P<0.05, **P<0.01 when comparing Cy/+ 2DG and Cy/+ vehicle at each time point.
#P<0.05, # # P<0.01 when comparing Cy/+ and +/+ group. (D) Urine albumin excretion in Cy/+ and +/+ rats after 5-week treatment with 2DG or vehicle. (E)
SDS-polyacrylamide gel electrophoresis of urine samples from Cy/+ and +/+ rats after 5-week treatment with 2DG or vehicle. (F) Lactate content in the
kidneys of Cy/+ and +/+ rats after treatment with 2DG or vehicle.
doi:10.1371/journal.pone.0146654.g004
Glycolytic Inhibition in PKD
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Phosphorylation of AMPK-α was reduced in the kidney lysate from Cy/+ rats as compared to
+/+ rats. Treatment with 2DG significantly increased AMPK-α phosphorylation in the kidneys
of Cy/+ rats (Fig 6A). Next, we studied the effect of 2DG on the phosphorylation of two key
kinases previously known to be activated in PKD, i.e. extracellular signal-regulated kinase
(ERK; mitogen-activated protein kinase [MAPK] pathway) and p70 S6K (mTOR pathway). As
shown in Fig 6B and 6C, phosphorylation of both ERK and p70 S6K were increased in the kid-
ney of Cy/+ rats as compared to +/+ rats. Treatment with 2DG led to a significant reduction in
the phosphorylation of ERK (Fig 6B), but there was no effect on the phosphorylation of p70
S6K (Fig 6C). Interestingly, 2DG treatment led to increased Akt phosphorylation (Fig 6D),
which may likely explain the lack of an observable effect on p70 S6K as activation of Akt is
known to counteract the effect of increased AMPK phosphorylation on p70 S6K activation.
Fig 5. Effect of 2DG treatment on cell proliferation and apoptosis in Han:SPRD Cy/+ rats. (A) Representative images of Ki67 staining of cyst-lining
epithelium in kidneys of Cy/+ rats treated with 2DG or vehicle. (B) Quantification of Ki67-positive nuclei in kidneys of Cy/+ rats after 5-week treatment with
2DG or vehicle. (C) Western blot analysis of active caspase-3 in kidneys from Cy/+ rats after treatment with 2DG or vehicle.
doi:10.1371/journal.pone.0146654.g005
Fig 6. Effect of 2DG treatment on cellular signaling pathways in vivo.Measurements of phosphorylation levels of (A) AMPK, (B) ERK, (C) S6K, and (D)
Akt usingWestern blot analysis in the kidneys of 10 week old +/+ and Cy/+ rats following 5-week treatment with 2DG or vehicle.
doi:10.1371/journal.pone.0146654.g006
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Previous studies have shown that activation of mTOR signaling is connected to enhanced
glycolysis [18]. We therefore examined the effect of direct mTOR inhibition on the enhanced
glycolysis which we observed in primary human cell cultures of ADPKD cells. Treatment with
the mTOR inhibitor rapamycin (50 nM) reduced the enhanced mRNA expression of glycolytic
genes (Hk1, Hk2, Pkm2) in ADPKD cells and also reduced the enhanced levels of lactate in the
cell culture medium (Fig 7A–7D). In line with this, the expression of glycolytic genes and lac-
tate production was also inhibited with the AMPK agonist metformin (2 mM), further empha-
sizing the importance of mTOR in glycolysis regulation (Fig 7A–7D).
Discussion
In the present study we show that Han:SPRD Cy/+ rats display increased transcript levels for
glycolysis enzymes and decreased transcript levels for gluconeogenesis enzymes in the kidney.
Lactate and ATP levels were also increased in the kidneys and in TEC cultures of Cy/+ rats
compared to wild type +/+ kidneys. Similar findings were obtained in cultured TEC derived
from patients with ADPKD. Importantly, administration of 2DG, a glycolytic inhibitor,
retarded cyst progression, improved renal function in Han:SPRD Cy/+ rats and was associated
with reduced intrarenal lactate levels and normalization of altered signaling pathways. Taken
together our data suggest that in PKD there is metabolic reprogramming towards enhanced
aerobic glycolysis, a phenomenon which is known as the Warburg effect, after its discoverer
Otto Warburg.
Recently, Rowe et al. reported that mutation of Pkd1 results in enhanced glycolysis in a
mouse model of PKD and in kidneys from patients with ADPKD [8,19]. Metabolomic profiling
of the cell culture medium of Pkd1-deficient mouse embryonic fibroblasts showed increased
glucose uptake and lactate production. The authors also found that treatment with 2DG
delayed cyst growth in two rapidly progressive mouse models of PKD. However, the duration
of the treatment with 2DG was extremely short (2 days), which does not account for the slowly
progressive nature of the disease. In addition, the effect of 2DG on renal function could not be
assessed due to the rapidly progressive nature of the models. More recently, Chiaravalli et al.
used an orthologous and slowly progressive murine PKD model created by inducible inactiva-
tion of the Pkd1 gene postnatally and found that 2DG also had beneficial effects on cyst growth
at a lower dose (100 mg/kg for 5 days per week for 2 months) [20].
Increased glycolysis has been previously reported in proliferating cells which require altered
metabolism to efficiently incorporate nutrients such as glucose into biomass. Cancer cells, for
instance, primarily metabolize glucose by glycolysis, whereas most normal cells completely
catabolize glucose by oxidative phosphorylation [21]. This shift to aerobic glycolysis with
increased lactate production, coupled with increased glucose uptake, is likely used by prolifer-
ating cells to promote the efficient conversion of glucose into the macromolecules needed to
construct a new cell [22].
It has been shown that the Warburg effect is associated with defective mitochondrial respi-
ration in the context of a hypoxic environment [23]. Similar to cancer cells, cyst epithelial cells
in polycystic kidney disease are exposed to hypoxia and display mitochondrial dysfunction
[24,25,26,27]. Furthermore it has been shown that cyst epithelial cells display a high rate of
apoptosis, a process which is tightly regulated at the level of mitochondria [28]. Increased apo-
ptosis in polycystic Han:SPRD rat kidneys was shown to be due to the activation of caspase-3
and dysregulation of the balance between pro- and anti-apoptotic Bcl-2 family members, spe-
cifically a down-regulation of anti-apoptotic Bcl-XL [29]. Zamzami et al. have shown that apo-
ptosis is closely related to mitochondrial impairment [30]. There is also a high level of
mitochondrial DNA (mtDNA) damage in apoptotic cells [31]. It is therefore conceivable that
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damage to the mtDNA would cause malfunction in the respiratory chain in PKD, forcing the
cyst epithelial cells to use the aerobic glycolysis pathway to generate ATP.
The glucose analog 2-deoxyglucose (2DG) acts as a competitive inhibitor of glucose metabo-
lism.[32] Upon transport into the cells, 2DG is phosphorylated by hexokinase to 2DG-P. How-
ever, unlike G-6-P, 2DG-P cannot be further metabolized by phosphohexose isomerase, which
converts G-6-P to fructose-6-phosphate [33]. Thus 2DG-P is trapped and accumulates in the
Fig 7. Effect of selected inhibitors on the glycolysis pathway in vitro. Real-time quantitative PCR analysis of the genes coding for glycolytic enzymes (A)
Hk1, (B) Hk2, and (C) Pkm2 in primary cell cultures of human ADPKD cells following incubation with rapamycin (50 nM) or metformin (2 mM). (D) Lactate
production in the supernatant of NHK and ADPKD cells, and response to inhibitors.
doi:10.1371/journal.pone.0146654.g007
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cells, leading to inhibition of glycolysis mainly at the step of phosphorylation of glucose by
hexokinase. Inhibition of this rate-limiting step by 2DG causes a depletion of cellular ATP,
leading to blockage of cell cycle progression and cell death in vitro [34]. The anti-tumor effect
of 2DG has been well characterized in animal models and human clinical trials [35,36,37]. The
feasibility of using a glycolytic inhibitor in a defined and progressive rat model of PKD has not
been tested yet. In the current study, we investigated the therapeutic potential of 2-deoxyglu-
cose (2DG) in Han:SPRD Cy/+ rats, a well-known animal model of PKD which develop slowly
progressing renal cysts resembling human ADPKD.
A major complication of polycystic kidney disease is the deterioration of renal function.
Glomerular filtration rate (GFR) significantly decreases towards the later stage of the disease,
requiring the patients to initiate renal replacement therapy. Delaying the loss of renal function
has therefore been a major therapeutic aim in PKD. In our study we show for the first time that
2DG improved different parameters of renal function (clearances for creatinine, BUN and uric
acid). 2DG also ameliorated albuminuria, a common biomarker of altered and progressively
deteriorating renal function in PKD. Taken together our data suggest that 2DG or related mol-
ecules may have a beneficial therapeutic potential for patients with ADPKD.
Interestingly, we observed that either direct inhibition of mTOR signaling using rapamycin
or indirect inhibition using the AMPK agonist metformin reversed the glycolytic phenotype in
ADPKD cells in vitro. Furthermore, we found that phosphorylation of ERK1/2 was signifi-
cantly reduced in Cy/+ upon treatment with 2DG, which likely explains the observed effect of
2DG on cell proliferation. Interestingly, treatment of 2DG did not affect the phosphorylation
status of S6K which is highly enhanced in Cy/+ kidneys as compared to wild-type rats. This
could be explained by 2DG-mediated activation of the survival signal PI3K/Akt pathway,
which counteracts the effect of 2DG via ERK and AMPK. As previously described, mTOR
functions as a central node in a complex net of signaling pathways; it integrates signals from
the Akt, ERK, and AMPK pathways and plays an important role in regulating protein biosyn-
thesis, cellular growth, and proliferation [38,39]. Fig 8 summarizes the various signaling
Fig 8. Schematic diagram showing the interplay of various signaling pathways involved in the regulation of glycolysis in polycystic kidney
disease.
doi:10.1371/journal.pone.0146654.g008
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pathways involved in the regulation of glycolysis in ADPKD that have been investigated in this
study.
Taken together, our results show that the cystic kidneys of Han:SPRD Cy/+ rats display
enhanced aerobic glycolysis which likely plays an important role in the pathogenesis of PKD.
The administration of 2DG, a potent glycolytic inhibitor, markedly delayed the loss of renal
function and retarded cyst development Han:SPRD Cy/+ rats with PKD. Targeting the glyco-
lytic pathway may therefore present a novel therapeutic strategy to control cyst growth in poly-
cystic kidney disease.
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